Welcome to our dedicated page for NKGen Biotech news (Ticker: NKGN), a resource for investors and traders seeking the latest updates and insights on NKGen Biotech stock.
NKGen Biotech, Inc. (OTC: NKGN) is a clinical-stage biotechnology company headquartered in Santa Ana, California, focused on autologous and allogeneic natural killer (NK) cell therapeutics. The NKGN news feed highlights company announcements, scientific presentations, regulatory updates, and corporate developments that shape its NK cell therapy programs.
Readers can find detailed coverage of NKGen’s work on troculeucel, a patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate and the International Nonproprietary Name (INN) for SNK01. News items include presentations on troculeucel’s mechanism of action and biomarker data in Alzheimer’s disease, as well as updates on its evaluation across multiple neurodegenerative diseases through clinical trials and an FDA Expanded Access Program authorization.
The news stream also features information on NKGen’s allogeneic NK cell therapy, SNK02, in solid tumors, including scientific and early clinical findings shared at immuno-oncology conferences. Corporate news covers NKGen’s acquisition of a majority equity stake in NKGen Biotech Korea Co., Ltd. (formerly NKMax Co., Ltd.), governance developments at NKGen Korea, and strategic partnerships such as its collaboration with HekaBio in Japan to advance troculeucel under Japan’s regenerative medicine framework.
In addition, NKGen issues updates on its trading status on the OTC Expert Market, clarifying quotation practices and reporting steps taken to address reporting obligations. Investors and observers can use the NKGN news page to follow how NKGen communicates progress in its NK cell therapy pipeline, regional collaborations, manufacturing and intellectual property consolidation, and interactions with regulators and capital providers.
NKGen Biotech (OTC: NKGN) has secured $2 million in funding from a Japanese strategic investor through a common equity PIPE with warrants priced at $0.25 per share. The funding aims to help the company regain compliance with reporting obligations and listing standards after facing challenges from its former parent company NKMax's bankruptcy in June 2024.
The company's stock will temporarily move to the OTC Expert Market, limiting trading accessibility, with plans to uplist to OTCQB once SEC filings are current. NKGen is developing troculeucel, an NK cell therapy for Alzheimer's and neurodegenerative diseases, and is currently ramping up its Phase 2 clinical trial. The company expects to acquire a majority stake in NKMax, consolidating key IP rights across Asia, and aims to eventually return to Nasdaq or NYSE American listing.
NKGen Biotech (OTC: NKGN) has administered the first dose of troculeucel, an expanded autologous NK cell therapy, to a mild-stage Alzheimer's patient under FDA compassionate use authorization. The patient had shown continued cognitive decline despite treatment with lecanemab, an amyloid-targeting therapy.
The treatment is being conducted in collaboration with Dr. Anita Fletcher at AdventHealth Neuroscience Institute. While NKGen's current Phase 2a trial focuses on moderate-stage Alzheimer's, this marks their first potential expansion into mild Alzheimer's treatment, particularly for patients not responding to first-line therapies.
Troculeucel has demonstrated promising characteristics, including the ability to cross the blood-brain barrier and improve levels of various proteins in cerebrospinal fluid while reducing neuroinflammation.
NKGen Biotech (OTC: NKGN) announced that Chairman & CEO Paul Y. Song, M.D. has made a personal investment of $2.65 million in the company through shares and warrants. The funding comes from proceeds of Dr. Song's recent sale of Fuse Biotherapeutics, which he co-founded. This investment supplements $3.0 million in funding advances from AlpineBrook Capital in 2025, beyond their previous $5.5 million proceeds and $4 million commitments in convertible notes.
The new capital will be used to accelerate NKGen's Phase 2 clinical trial for Alzheimer's Disease, reduce company payables, and cover working capital and compliance-related expenses. The AlpineBrook advances are secured by personal guarantees from Dr. Song and Interim CFO James Graf.
NKGen Biotech (OTC: NKGN) announced an upcoming presentation of Phase 1 clinical data for troculeucel, their cryopreserved expanded autologous NK cell therapy for moderate Alzheimer's disease (AD), at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting. The presentation, titled "Use of Expanded Non-genetically Modified Natural Killer Cells (Troculeucel) with Enhanced Cytotoxicity in Patients with Alzheimer's Disease. Preliminary Clinical and Biomarker Results," will be delivered by Dr. Paul Y. Song on May 14, 2025, at 2:30 PM CT in New Orleans.
NKGen Biotech (OTC: NKGN) has announced that its Chairman and CEO, Dr. Paul Y. Song, will present at the 7th China International Biotechnology Conference & Exhibition (BIOTEC-CHINA 2025) in Beijing from April 16-18, 2025.
The presentation, scheduled for April 17, 2025, at 10:20 am CST, will focus on troculeucel, the company's NK cell therapeutic treatment for Alzheimer's and Parkinson's disease. Dr. Song will discuss promising results from Phase 1 clinical trials and compassionate use cases, along with updates on their ongoing Phase 1/2a clinical trial for moderate Alzheimer's disease.
BIOTEC-CHINA 2025 is expected to attract approximately 1,500 biotechnology and pharmaceutical professionals, offering networking opportunities and covering various life science topics including drug discovery, biomanufacturing, genomics, nanotechnology, and cell therapy.
NKGen Biotech (OTC: NKGN) presented updated Phase 1 clinical data for troculeucel, their NK cell therapy for moderate Alzheimer's disease (AD), at AD/PD™ 2025. The trial administered the highest dose of 6 billion cells every three weeks to three patients with moderate AD.
Key findings after 12 months: Two patients completed all 17 doses, showing improvement from moderate to mild AD within 3 months. One patient achieved a CDR-SB score of 4.5, near the mild cognitive impairment threshold. No drug-related adverse reactions were reported. All patients showed decreased GFAP levels in CSF and plasma at 6 months, while the two completing patients demonstrated improved Amyloid Beta 42/40 ratios at 12 months.
The company is now proceeding with the randomized, placebo-controlled Phase 2a portion of the study, expecting significant cognitive and biomarker differences between treatment and placebo groups within 6 months.
NKGen Biotech (OTC: NKGN) has announced its upcoming presentation at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025), scheduled for April 1-5, 2025, in Vienna, Austria. The event will also be available online.
Dr. Paul Y. Song, Chairman and CEO of NKGen, will present updated data from their Phase 1/2a clinical trial of troculeucel NK cell therapy for moderate Alzheimer's disease. The presentation will cover three-month cognitive and biomarker results from the Phase 1 cohort, along with new six-month analysis data.
AD/PD™ 2025 is a leading international conference that gathered over 4,700 participants from 70+ countries and featured 2,250 abstracts in 2024. The conference serves as a platform for experts to share the latest developments in Alzheimer's and Parkinson's research, clinical trials, and treatments.
NKGen Biotech (OTC: NKGN) announced its participation in the 13th Annual Alzheimer's & Parkinson's Drug Development Summit in Boston from March 18-20, 2025. Chairman and CEO Paul Y. Song will present on troculeucel, the company's autologous, non-genetically modified NK cell therapy for neurodegenerative diseases.
The presentation will focus on troculeucel's mechanism and promising Phase 1 clinical trial results, which led to FDA Fast Track designation for moderate Alzheimer's Disease and a new Investigational New Drug designation for Parkinson's Disease. The company also plans to explore troculeucel's potential in Frontotemporal Dementia and post-stroke/traumatic brain injury treatment.
The Summit, featuring over 150 experts, is the only industry-focused event covering the complete drug development process from discovery to commercialization, highlighting advancements in neurodegenerative therapeutics, presymptomatic diagnosis, and new treatment modalities.
NKGen Biotech (NKGN) announced its delisting from Nasdaq Global Market effective March 4, 2025, due to non-compliance with market value requirements. The company will transition to OTC Markets starting March 5, 2025, trading under symbols 'NKGN' for common stock and 'NKGNW' for warrants.
The company has cancelled its previously planned 1-for-6 reverse stock split and intends to apply for the OTCQX platform, maintaining SEC reporting compliance. NKGen's Phase 2a Alzheimer's trial enrollment is expected to complete by Q2 end, with initial readout planned for late 2025.
Despite challenges related to their former parent company NKMAX's financial restructuring, NKGen highlighted progress in their Alzheimer's program, including FDA Fast Track designation, Phase 1 results publication, and presentations at major conferences in 2024. The company aims to eventually re-list on Nasdaq once meeting listing requirements.
FAQ
What is the current stock price of NKGen Biotech (NKGN)?
What is the market cap of NKGen Biotech (NKGN)?
